Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. It focuses on the development of oligomer-directed vaccine and monoclonal antibody specifically for the synapse-damaging oligomers. The company was founded by Anders Sandberg and Thorleif Roland Hard on August 17, 2011 and is headquartered in Molndal, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company